Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Neurofibromatosis Type 2
NCT01419639Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in neurofibromatosis type 2 (NF2), sponsored by NYU Langone Health. Started Oct 2011; status: completed.
02
Drugs
everolimus
03
Conditions
neurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on NCT01419639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01419639.